https://www.selleckchem.com/pr....oducts/R788(Fostamat
02). Greater values of CTx at baseline were associated with a greater rate of adverse events leading to discontinuation (P = 0.04), gastrointestinal adverse events (P = 0.0001), musculoskeletal adverse events (P = 0.04), and mortality (P = 0.04). Greater values of PINP at baseline were associated with greater rates of gastrointestinal adverse events (P = 0.02) at the last follow-up. The present analysis supports the adoption of BMTs during pharmacological therapy setting of patients suffering from osteoporosis. I, sy
Like
Comment
Share
